One-Year Mortality 8.6 Percent After ED Visit for Opioid Overdose
via HealthDayTHURSDAY, May 14, 2026 -- One-year mortality is 8.6 percent among individuals after an emergency department visit for an opioid overdose, according to a research letter published online May 7 in the Journal of the American Medical Association.
Robert A. Kleinman, M.D., from the Centre for Addiction and Mental Health in Toronto, and colleagues examined one-year mortality among opioid overdose survivors in Ontario, Canada, to characterize postoverdose risk in the fentanyl era.
The cohort included 28,488 individuals with an emergency department visit for a nonfatal opioid overdose to 179 emergency departments. The researchers found that 8.6 percent of individuals died within one year (91.4 per 1,000 person-years); 63.7 percent of deaths were from opioid overdoses. Overall, 21.2 percent of individuals had at least one repeat opioid overdose during the one-year follow-up (252.5 per 1,000 person-years). Individuals with a prior opioid overdose in the preceding five years had particularly elevated one-year mortality (11.5 percent; 123.6 per 1,000 person-years). Incidence rates were highest immediately after discharge, with 0.6 percent of individuals dying and 2.4 percent experiencing a repeat opioid overdose within seven days of discharge. Within 30 days, 1.6 and 5.6 percent of individuals died and experienced a repeat overdose, respectively.
"This study identified high risks of death and repeat opioid overdose among survivors of nonfatal opioid overdose in the fentanyl era, with particularly elevated risks in the days immediately following emergency department discharge, underscoring the need for tailored clinical interventions for this high-risk population," the authors write.
One author disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2026-05-15 02:41
Read more
- Online Program Soothes Post-Trauma Stress In Injured Children
- LFSPRO Model Shows Superior Discrimination for Li-Fraumeni Syndrome
- Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema
- Very Few Patients With HIV Report Using Long-Acting Injectable ART
- Bullying, Politics Harm Mental Health Of Gender-Diverse Teens
- Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions